Correlation between serum BDNF，Val66Met gene polymorphism and clinical symptoms in early Parkinson’s disease
- VernacularTitle:血清BDNF、Val66Met基因多态性和早期帕金森病临床症状的相关性
- Author:
Qing WU
1
;
Ming YU
1
;
Hongyan LIU
1
Author Information
- Publication Type:Journal Article
- Keywords: BDNF ； Val66Met gene polymorphism ； Early Parkinson’s disease ；Anxiety and depression
- From: Journal of Apoplexy and Nervous Diseases 2022;39(5):425-429
- CountryChina
- Language:Chinese
- Abstract: To investigate the correlation between serum Brain-derived neurotrophic factor （BDNF），Val66Met gene polymorphism and clinical symptoms in patients with newly diagnosed Parkinson’s disease （PD）. Methods A total of 62 early PD patients and 46 healthy controls were collected from Ningbo First Hospital. General demographics，Hamilton Anxiety Scale （HAMA），Hamilton Depression Scale （HAMD），Orthostatic Hypotension （OH） or not，serum BDNF levels，Val66Met genotype were examined in all subjects，duration of disease，Hoehn-Yahr （HY） Rating Scale，Unified Parkinson’s Disease Rating Scale motor scores （UPDRS-Ⅲ），symptom classification （tremor type，rigid type or mixed type） were also assessed in patients. Results PD patients had significantly higher HAMA，HAMD scores，incidence of OH and lower BDNF levels than controls，there was no significant difference in the distribution of Val66Met gene polymorphism between the two groups. Multiple linear regression revealed that BDNF levels were negatively associated with HAMA （P=0.014） and HAMD （P=0.013） scores in PD patients，however，no significant correlation were found between Val66Met polymorphism and clinical symptoms. Conclusion Evident non-motor symptoms can occur in early PD patients，serum BNDF levels were correlated with the degree of anxiety and depression in patients，and Val66Met gene polymorphism may not play an important role in the course of disease.
- Full text:2024072422480368555血清BDNF、_Val66Met基因多态性和早期帕金森病临床症状的相关性.pdf
